Cite
HARVARD Citation
Rogé, M. et al. (2023). Randomized phase II trial in prostate cancer with hormone-sensitive OligometaSTatic relapse: Combining stereotactic ablative radiotherapy and durvalumab (POSTCARD GETUG P13): Study protocol. Clinical and translational radiation oncology. p. . [Online].